GENE ONLINE|News &
Opinion
Blog

Novavax to Seek Regulatory Approval After COVID-19 Vaccine Displays 90% Efficacy in US Trial

by Rajaneesh K. Gopinath
Share To

June 14th, 2021 – Earlier today, Novavax announced that its COVID-19 vaccine, NVX-CoV2373 met the primary endpoint in the Phase 3, PREVENT-19 trial conducted in the US and Mexico.

Results from the 29,960 participant study demonstrated that the recombinant nanoparticle protein-based vaccine registered an overall efficacy of 90.4% and conferred 100% protection against moderate and severe disease. Earlier, in a Phase 3 trial conducted in the UK, the vaccine had demonstrated a 96.4% efficacy against mild, moderate, and severe disease caused by the original COVID-19 strain.

“Today, Novavax is one step closer to addressing the critical and persistent global public health need for additional COVID-19 vaccines. These clinical results reinforce that NVX-CoV2373 is extremely effective and offers complete protection against both moderate and severe COVID-19 infection,” said Stanley C. Erck, President and CEO of Novavax.

“Novavax continues to work with a sense of urgency to complete our regulatory submissions and deliver this vaccine, built on a well understood and proven platform, to a world that is still in great need of vaccines.”

 

Fourth Vaccine Option

With these positive results, the Maryland-based company plans to submit an application for FDA’s emergency approval in the third quarter of this year. If approved, the company would be heading towards its goal of producing 100 million and 150 million doses per month in the third and fourth quarters of 2021, respectively.

Additionally, the approval would give the US a fourth vaccine option behind Pfizer/BioNTech, Moderna, and J&J’s vaccines. Since the US government has already procured enough doses from the three manufacturers to vaccinate its population, the FDA might urge Novavax to apply for full approval.

Just days earlier, the FDA rejected the EUA of Covaxin, India’s indigenous COVID-19 vaccine manufactured by Bharat Biotech. Instead, the agency asked Ocugen, Bharat Biotech’s US partner, to pursue full approval.

Nevertheless, with the increasing COVID-19 cases caused by variants, NVX-CoV2373 could very well prove to be a booster shot to the public. Novavax mentioned that the efficacy endpoints of the PREVENT-19 trial were accrued from January 25 through April 30, 2021, when COVID-19 cases in the US were dominated by the Alpha (B.1.1.7) variant, first identified in the UK. Other strains, including Variants of Interest (VoI) and Variants of Concern (VoC), were also on the rise.

“PREVENT-19 confirms that NVX-CoV2373 offers a reassuring tolerability and safety profile,” said Gregory M. Glenn, M.D., President of Research and Development, Novavax. “These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus. Our vaccine will be a critical part of the solution to COVID-19, and we are grateful to the study participants and trial staff who made this study possible, as well as our supporters, including the U.S. Government.”

Besides, Novavax’s vaccine could also help meet the increasing demand for COVID-19 jabs in other countries. “Many of our first doses will go to … low- and middle-income countries, and that was the goal to begin with,” Stanley Erck told The Associated Press.

Related Article: COVID-19: Rise in UK Cases Trigger Global Concerns Over “Highly Infectious” Delta Variant

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Controversy Surrounds Jay Bhattacharya’s Nomination as NIH Director
2025-03-05
Study Reveals Distinct Immune Signatures in Myocarditis Linked to COVID-19 and Vaccines
2025-02-25
Study Reveals Impact of Optimism and Pessimism on Resilience and Health Behaviors During COVID-19
2025-02-24
LATEST
Eli Lilly’s Orforglipron Shows Phase 3 Success: First Oral GLP-1 Drug for Type 2 Diabetes and Weight Loss
2025-04-21
Dupixent Makes History with FDA Approval as First New CSU Treatment in Over a Decade
2025-04-20
Multiple PCV Doses May Be Needed for Immunocompromised Type 2 Diabetics to Maintain Protection, Study Finds
2025-04-19
Multiple PCV Doses May Be Needed for Immunocompromised Individuals with Type 2 Diabetes
2025-04-19
Dr. Lauren Krupp, FAAN, Advocates Early Intervention and Family Support in Pediatric MS Treatment.
2025-04-19
Dr. Lauren B. Krupp Recommends Early, Aggressive Treatment with High-Efficacy Therapies for Pediatric Multiple Sclerosis
2025-04-19
GSK’s Blenrep Scores World-First Approval in UK for Multiple Myeloma
2025-04-17
EVENT
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-04-26
SABPA OC/LA 17th Annual Biomedical Forum
Irvine, California, United States
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
Scroll to Top